A month has gone by since the last earnings report for Qiagen (QGEN) . Shares have added about 1.6% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. QIAGEN Q1 Earnings and Revenues Top, Margins Rise QIAGEN N.V ...

QIAGEN N.V. (QGEN) is likely to grow in the coming quarters, backed by its strong potential in the next- generation sequencing (NGS) platform. QIAGEN’s long-term business strategy involves forming partnerships with academic, corporate and other partners for product development, which is very promising. A strong solvency position also buoys optimism. Meanwhile, concerns loom over the impact of macroeconomic challenges on QIAGEN’s operations. Competitive disadvantages may also hurt its performance. In the pas ...

QIAGEN N.V. (QGEN) recently announced the receipt of the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation for its updated version of its clinical decision support platform — QIAGEN Clinical Insight (QCI) Interpret. The recent regulatory approval ensures greater patient protection, transparency of information and traceability of data. For investors’ note, QCI Interpret is a software that aids in i ...

QIAGEN N.V. (QGEN) recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the test is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets. The latest development will strongly boost the company’s Molecular Diagnostics business. Significance of the QIAstat-Dx Respiratory Panel Plu ...

QIAGEN N.V. (QGEN) recently entered into a cooperative research and development agreement (CRADA) with the Federal Bureau of Investigation (FBI). The deal advances a novel test for its QIAcuity digital PCR devices that will enhance forensics by improving the quantification of DNA in human samples. The recent development will strengthen QIAGEN’s leading position in the human identification (HID) and forensics business. More on the News As a federally accredited laboratory, the FBI performs research and devel ...

QIAstat-Dx呼吸道面板加综合测试 - QIAGEN宣布美国食品和药物管理局（FDA）已批准QIAstat-Dx呼吸道面板加综合测试用于临床使用[1] - QIAstat-Dx呼吸道面板加综合测试旨在支持临床决策，涵盖21种病毒和细菌目标[2] - QIAstat-Dx呼吸道面板加综合测试能够快速扩增多个基因靶标，使用实时PCR技术，在约一小时内提供结果，操作时间少于一分钟[2] - QIAstat-Dx呼吸道面板加综合测试可改善患者护理，支持负责任的抗菌药物管理，并减轻医疗系统负担[3] - QIAGEN正致力于在美国扩展QIAstat-Dx产品组合，目前正在FDA审查胃肠道面板和脑膜炎/脑炎面板[3] - QIAstat-Dx等综合测试系统已被证明可以提高共感染的检测，减少额外测试的需求[4] QIAstat-Dx分析仪 - QIAGEN最近推出了QIAstat-Dx分析仪2.0，引入了远程结果应用程序，允许用户在任何地点直接查看、评论和确认诊断测试结果[5] - QIAstat-Dx可提供两种格式：集成多达四个分析模块的QIAstat-Dx分析仪版本，以及提供每天高达160次测试的QIAstat-Dx Rise高容量版本[6] QIAGEN - QIAGEN是全球领先的Sample to Insight解决方案提供商，为超过50万客户提供分子诊断和生命科学解决方案[8]

Have you evaluated the performance of Qiagen's (QGEN) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this diagnostic products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth ...

Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended March 31, 2024 Table of Contents Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2 2023 Condensed Consolidated Statements of Income (unaudited) for the three months ended 4 March 31, 2024 and 2023 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three months 5 ended March 31, 2024 and 2023 Condensed Consolid ...

QIAGEN N.V.’s (QGEN) first-quarter 2024 adjusted earnings per share (EPS) were 46 cents and 47 cents at constant exchange rate (CER), down 9.8% year over year. However, the figure topped the Zacks Consensus Estimate by 4.6%. The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. The GAAP EPS for the quarter was 36 cents, down 2. ...

For the quarter ended March 2024, Qiagen (QGEN) reported revenue of $458.8 million, down 5.5% over the same period last year. EPS came in at $0.46, compared to $0.53 in the year-ago quarter. The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS surprise was +4.55%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...